AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03205163 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIVV001 (High Dose)
Description: Participants received single IV high dose of BIVV001 65 IU/kg.
Study NCT01643967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sunflower oil
Description: The research subjects allocated to this treatment arm will receive Sunflower Oil supplied by Philozon. Sunflower oil should be applied once daily for 60 days, it immediately after cleansing site where the lesion is present.
Study NCT01643967 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ozone Therapy
Description: The research subject will receive topical and rectal insufflation of ozone three times a week on alternate days for two months or at least 12 sessions.
Study NCT03099616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
Study NCT00346125 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: fludeoxyglucose F 18
Description: FDG is a radioactive sugar equal to a uniform whole-body exposure of approximately 1.5 rem for each scan. Post-operative radiation therapy may be given according to institutional guidelines in patients felt to have close surgical margins.
Study NCT03099616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Desflurane delivery will be controlled using a agent specific vaporiser. The dial concentration of the vaporiser will be adjusted to maintain a BIS of 50-55 in the patients.
Study NCT03138421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX-1431 HCl
Description: ABX-1431 HCl, capsules, 20 mg
Study NCT03138421 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT03597620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metaderm
Description: Metaderm cream and spray will be apply to subjects scalp and body.
Study NCT05138510 — intervention group
Intervention type: BEHAVIORAL
Intervention: Focus Group
Description: Providers with extensive training and expertise in the subject will lead the virtual focus groups over Zoom using a semi-structured guide. Topics will focus on education received from the health care team, information received from outside sources, and patient recommendations on the type and timing of information preferred.~We will create an analytic report based on the focus group findings, which will be used to inform the development of educational material.~Sexual well-being is currently measured longitudinally on a 0-100 point scale as a component of a validated patient-reported outcome measures (PROM) survey (BREAST-Q) distributed to all breast cancer patients. These scores will be analyzed in patients with and without educational interventions for comparison.
Study NCT01862913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive-behavioral therapy
Description: The intervention arm will receive eight sessions of computer-assisted CBT plus usual medical treatment, as described in the AUGE Clinical Guidelines for Depression. Computer-assisted CBT sessions will be delivered on a weekly basis and assisted by trained psychologists in face-to-face meetings. The program is called 'Yo pienso, siento y actúo mejor' (YPSA-M); in English, 'I think, feel, and behave better'. Topics covered in the program will include information on symptoms and causes of depression, treatment options, problem-solving techniques and other cognitive-orientated strategies to challenge negative thoughts.
Study NCT01377207 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary PCI
Description: Thrombus aspiration and hystopathological analysis, Optical Coherence Tomography assessment of STEMI culprit vessel, Primary PCI with Drug Eluting Stent implantation; Repeat OCT assessment of culprit vessel at 9 monts follow-up
Study NCT01862913 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care treatment
Description: The control arm will receive treatment as usual from the primary care clinics. The professionals in the primary care centers will be instructed to follow the AUGE Clinical Guidelines for Depression.
Study NCT02318342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Patients with prosthetic valve abnormalities suggestive of thrombus will be administered anticoagulation therapy with Vitamin K antagonists (Warfarin) for 3 months with goal INR 2-3, followed by repeat contrast CT of the chest and transthoracic imaging. Repeat imaging following 3 months of anticoagulation therapy is performed to evaluate the response to anticoagulation therapy.
Study NCT02927392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate
Description: A subset of premenopausal women will receive GnRHAG (leuprolide acetate) 3.75 mg/mo by intramuscular injection every 4 weeks for 24 weeks (6 doses).
Study NCT00782717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac ophthalmic suspension, 0.1% (NEVANAC)
Description: 1 drop TID beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery.
Study NCT00782717 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nepafenac ophthalmic suspension vehicle
Description: 1 drop TID beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
Study NCT00782717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone acetate ophthalmic suspension (OMNIPRED)
Description: One drop in the study eye 4 times daily (morning, late morning, late afternoon, and bedtime)for two weeks postsurgery.
Study NCT00782717 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone acetate ophthalmic suspension (OMNIPRED)
Description: One drop in the study eye 4 times daily (morning, late morning, late afternoon, and bedtime)for two weeks postsurgery.
Study NCT02446717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493, ABT-530
Description: ABT-493 (tablet) dosed with ABT-530 (tablet)
Study NCT02446717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin (RBV)
Description: Tablet
Study NCT02446717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493/ABT-530
Description: Tablet; ABT-493 coformulated with ABT-530
Study NCT01669317 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 8-ounce glass of cherry juice
Description: You will be given an 8-ounce glass of cherry juice or artificial cherry juice to drink when you arrive at the Sleep Laboratory.
Study NCT01669317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 8-ounce glass of cherry juice
Description: You will be given an 8-ounce glass of cherry juice or artificial cherry juice to drink when you arrive at the Sleep Laboratory.
Study NCT01669317 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Artificial Cherry Juice
Description: You will be given an 8-ounce glass of artificial cherry juice
Study NCT01377207 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary PCI
Description: Thrombus aspiration and hystopathological analysis, Optical Coherence Tomography assessment of STEMI culprit vessel, Primary PCI with Drug Eluting Stent implantation; Repeat OCT assessment of culprit vessel at 9 monts follow-up
Study NCT01669317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial Cherry Juice
Description: You will be given an 8-ounce glass of artificial cherry juice
Study NCT02660164 — intervention group
Intervention type: DEVICE
Intervention: Nautilus BrainPulse Recording
Description: Comparison of Nautilus BrainPulse recordings in subjects who have a concussive event (Cohort A) to Nautilus BrainPulse recording in subjects who do not experience a concussive events (Cohort B or matched subjects to Cohort A). Recordings are obtained over a 2 week period every 2 to 3 days (at least 5 recordings per subject).
Study NCT03149172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Equimatrix®
Description: Ridge preservation bone grafting after tooth extraction
Study NCT03149172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bio-Oss®
Description: Ridge preservation bone grafting after tooth extraction
Study NCT03149172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endobon®
Description: Ridge preservation bone grafting after tooth extraction
Study NCT02307058 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: LEAD RT
Description: The multiparametric-MRI (MP-MRI) defined Gross Tumor Volume (GTV) will receive 12-14 Gy on the first day of treatment and then the prostate plus proximal seminal vesicles (SV), the Clinical Target Volume (CTV)1, will receive 76 Gy in 38 fractions (Fxs) at 2.0 Gy per Fx. For High Risk patients, the distal SVs may be treated to 56 Gy in 38 Fxs or full dose (CTV2), and the pelvic lymph nodes may be treated to 56 Gy in 38 Fxs (CTV3).
Study NCT02307058 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HEIGHT RT
Description: The MRI defined GTV(s) will receive a higher dose per day than the CTV by dose painting. The GTV(s) will receive an absolute dose of 91.2 Gy. Assuming an α/β ratio of 3.0, this would be equivalent to 98.5 Gy in 2.0 Gy fractions. The prostate plus proximal seminal vesicles (CTV1) will receive 76 Gy in 38 fractions (Fxs) at 2.0 Gy per Fx. For High Risk patients, the distal SVs (CTV2) may be treated to 56 Gy in 38 Fxs or full dose, and the pelvic lymph nodes (CTV3) may be treated to 56 Gy in 38 Fxs.
Study NCT01317251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention (without dairy products)
Description: Control diet without dairy products
Study NCT01317251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention (high milk content)
Description: Diet with a high content of milk (\~1200 mg Ca/d from milk)
Study NCT01317251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention (high cheese content)
Description: Diet with a high content of cheese (\~1200 mg Ca/d from cheese)
Study NCT02538042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Both groups will receive nicotine patches (21 mg/d if smoking ≥10 cigs/d or 14 mg/d if smoking \<10 cigs/d) to wear for 3 weeks prior to the quit date. After the quit date, both groups will wear the nicotine patch for 10 weeks. Participants that smoked ≥10 cigs/d will wear a 21 mg/d patch for 6 weeks, a 14 mg/d patch for 2 weeks, and a 7 mg/d patch for 2 weeks. Participants that smoked \<10 cigs/d will wear a 14 mg/d patch for 6 weeks, then step down to a 7 mg/d patch for 4 weeks.
Study NCT02587117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lycopene
Description: Each capsule contain 2 mg lycopene. Each patient was received two capsules of lycopene (total dose was 4 mg) single dose in morning for 2 months. Follow-up was done at base line, 2nd, 4th, 6th and 8th weeks of the therapy.
Study NCT02587117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Each capsule contain 20 mg prednisolone. Each patient was received two capsules of prednisolone (total dose was 40 mg) single dose in morning for 2 months. Follow-up was done at base line, 2nd, 4th, 6th and 8th weeks of the therapy.
Study NCT02538042 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine Patch
Description: Both groups will receive nicotine patches (21 mg/d if smoking ≥10 cigs/d or 14 mg/d if smoking \<10 cigs/d) to wear for 3 weeks prior to the quit date. After the quit date, both groups will wear the nicotine patch for 10 weeks. Participants that smoked ≥10 cigs/d will wear a 21 mg/d patch for 6 weeks, a 14 mg/d patch for 2 weeks, and a 7 mg/d patch for 2 weeks. Participants that smoked \<10 cigs/d will wear a 14 mg/d patch for 6 weeks, then step down to a 7 mg/d patch for 4 weeks.
Study NCT02538042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPECTRUM Nicotine Research Cigarettes (0.07 mg)
Description: For 3 weeks prior to their quit day, participants will switch to smoking SPECTRUM Nicotine Research Cigarettes instead of their usual brand.
Study NCT02538042 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SPECTRUM Nicotine Research Cigarettes (0.07 mg)
Description: For 3 weeks prior to their quit day, participants will switch to smoking SPECTRUM Nicotine Research Cigarettes instead of their usual brand.
Study NCT02538042 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MCE+
Description: During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view smoking-related environments and smoke their assigned cigarettes.
Study NCT02538042 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MCE-
Description: During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view nature environments and smoke their assigned cigarettes.
Study NCT03026881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Fluzoparib either at 20,30,40mg twice daily,capsule oral.
Study NCT03026881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Oral
Study NCT03026881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenous injection
Study NCT03854799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Eligible patients will receive:~CHEMORADIOTHERAPY PLUS AVELUMAB:~* CAPECITABINE 825 mg/sqm/bid p.o. 5 days/week~* EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 fractions over 5.5 weeks~* AVELUMAB 10 mg/Kg ev over 1 hour every 2 weeks at days 1, 14, 28, 42, 56, 70~Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion.
Study NCT03854799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Eligible patients will receive:~CHEMORADIOTHERAPY PLUS AVELUMAB:~* CAPECITABINE 825 mg/sqm/bid p.o. 5 days/week~* EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 fractions over 5.5 weeks~* AVELUMAB 10 mg/Kg ev over 1 hour every 2 weeks at days 1, 14, 28, 42, 56, 70~Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion.
Study NCT05301725 — intervention group
Intervention type: OTHER
Intervention: PPI regimen
Description: All patients received PPI regimen( lansoprazole or esomeprazole,bismuth amoxicillin,clarithromycin for14 days). Demographic data,treatment regimens, outcomes of therapy, adherence to therapy and adverse event were retrieved.
Study NCT03854799 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: EXTERNAL---BEAM IRRADIATION 50.4 GY
Description: Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion.
Study NCT00016328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV
Study NCT00016328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00016328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00217217 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echo-Planar Magnetic Resonance Imaging (EP-MRSI)
Description: variable-setting low-frequency MRI
Study NCT05301725 — intervention group
Intervention type: OTHER
Intervention: P-CAB regimen
Description: All patients received P-CAB regimen(vonoprazan,bismuth ,amoxicillin,clarithromycin for14 days). Demographic data,treatment regimens, outcomes of therapy, adherence to therapy and adverse event were retrieved.
Study NCT01596517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus ribavirin for HCV genotype 1
Description: Patients with genotype 1: treatment with peginterferon α-2a (Roche, Basel, Switzerland) 180 μg/week and daily ribavirin dose of 1,000 mg (for patients with body weight \<75kg) or 1,200 mg (for patients with body weight ≥75kg) for 48 weeks.
Study NCT00217217 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Echo-Planar Magnetic Resonance Imaging (EP-MRSI)
Description: variable-setting low-frequency MRI
Study NCT04671264 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sallowing VC during six weeks
Description: follow-up was required for at least 6 times, once every two weeks through the whole study.~For patients who had no colonoscopy examination within a year, colonoscopy was a must to exclude organic diseases.~These included blood routine, blood biochemistry, urine routine, fecal routine, fecal occult blood, thyroid stimulating hormone (TSH), blood pregnancy test and ECG examination. Patients should finish all the examination in the run-in period and at the end of treatment period.~Dairy cards were designed mainly for the record of the daily defecation of patients and filled out by the enrolled patients, and the content included date, whether the patients swallow capsules (time), whether the patients discharge capsules (time), defecation, defecation time, degree of defecation exertion(0\~4), BSF scale, complete or incomplete defecation, whether the patient had the sense of anal obstruction, whether manual assistance was applied, and whether first-aid medicine was used (bisacodyl).
Study NCT04671264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sallowing VC during six weeks
Description: follow-up was required for at least 6 times, once every two weeks through the whole study.~For patients who had no colonoscopy examination within a year, colonoscopy was a must to exclude organic diseases.~These included blood routine, blood biochemistry, urine routine, fecal routine, fecal occult blood, thyroid stimulating hormone (TSH), blood pregnancy test and ECG examination. Patients should finish all the examination in the run-in period and at the end of treatment period.~Dairy cards were designed mainly for the record of the daily defecation of patients and filled out by the enrolled patients, and the content included date, whether the patients swallow capsules (time), whether the patients discharge capsules (time), defecation, defecation time, degree of defecation exertion(0\~4), BSF scale, complete or incomplete defecation, whether the patient had the sense of anal obstruction, whether manual assistance was applied, and whether first-aid medicine was used (bisacodyl).
Study NCT03724929 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood samples will be systematically collected at W0, W2, W6, W14 and W52 for vedolizumab pharmacokinetic parameters, including the vedolizumab trough levels and the specific anti-vedolizumab antibody. A supplementary blood sample will be collected at W10 which is the point where a significant greater number of patients were in remission.
Study NCT03724929 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rectosigmoidoscopy
Description: Rectosigmoidoscopy will be performed in each center at time points W0, W10 and W52.
Study NCT03896802 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiological assesment
Description: 1. Arterial and mixed venous blood gas analysis.~2. Alveolar and physiologic dead space via volumetric capnometry, as well as carbon dioxide (CO2) production, end-tidal CO2 and mixed expired CO2~3. Respiratory system (Crs), chest wall (Ccw) and lung (Cl) compliance measurement via an end-inspiratory and end-expiratory pause.~4. Arterial blood pressure, central venous pressure (CVP), heart rate, cardiac output through the arterial pulse contour and transpulmonary thermodilution methods (PiCCO technology). Global end-diastolic volume, Intra-thoracic blood volume, Extravascular lung water will also be assessed. Respiratory hold maneuvers (at PEEP, and +10, +15 and +20 cmH2O) will be performed and CVP and cardiac output will be measured in the last 3 s of the 12 s inspiratory hold. Venous return curve will constructed and the zero-flow pressure recorded as the mean systemic filling pressure.~5. Urine flow in 1h and determination of the fractional excretion of sodium and creatinine.
Study NCT02720796 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PDX drug sensitivity testing
Description: Patient derived xenograft (PDX) models will be developed for each patient and drug activity assessed in their personalized PDX model. PDX drug sensitivity information will be provided to the treating physician.
Study NCT00031096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelaic Acid Gel 15% (Finacea, BAY39-6251)
Description: Azelaic Acid 15% gel (SH H 655 BA) applied topically two times per day.
Study NCT00031096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel (SH H 655 PBA)
Description: Vehicle gel (SH H 655 PBA) applied topically two times per day.
Study NCT03869905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aquamin®
Description: 4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day)
Study NCT03869905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aquamin®
Description: 4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day)
Study NCT03869905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo first then Aquamin®
Description: 4 capsules per day; 2 to be taken in the morning and 2 in the evening
Study NCT02452008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160mg of enzalutamide is administered orally once a day on days 1-28 of each cycle.
Study NCT02452008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2157299
Description: 150 mg of LY2157299 is administered orally twice a day on days 1-14 of each cycle.